Most Popular
-
1
NewJeans to terminate contract with Ador
-
2
Korean Air gets European nod to become Northeast Asia’s largest airline
-
3
NewJeans terminates contract with Ador, embarks on new journey
-
4
Chaos unfolds as rare November snowstorm grips Korea for 2nd day
-
5
‘VCHA, Katseye and Dear Alice are not K-pop groups,’ industry experts say
-
6
Ador claims exclusive contracts with NewJeans still valid
-
7
Japan will pay for failing to honor promises, minister says
-
8
‘Green aurora’ is Seoul's color of 2025
-
9
Firefighter holds truck driver for 45 minutes to save him from falling off bridge
-
10
[Herald Interview] Meet 1VERSE, first K-pop boy band to feature North Korean defectors
![[Herald Interview] Meet 1VERSE, first K-pop boy band to feature North Korean defectors](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/27/20241127050102_0.jpg&u=20241128174936)
![[Herald Interview] Meet 1VERSE, first K-pop boy band to feature North Korean defectors](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/27/20241127050102_0.jpg&u=20241128174936)
Daewoong Pharmaceutical to export Nabota to New Zealand, Israel, Ukraine
By YonhapPublished : Dec. 20, 2018 - 15:59
South Korean drugmaker Daewoong Pharmaceutical Co. said Thursday it has signed deals to sell its type A botulinum toxin drug in New Zealand, Israel and Ukraine.
The product, called Nabota, will be available in the three countries as early as 2020 in accordance with the three separate contracts, whose combined value amounts to $12 million, the company said.
The product, called Nabota, will be available in the three countries as early as 2020 in accordance with the three separate contracts, whose combined value amounts to $12 million, the company said.
Douglas Pharmaceuticals will market Nabota in New Zealand, Israel-based Luminera Derm., Ltd in Israel and Totis Pharma Group in Ukraine, corporate sources said.
"Daewoong Pharmaceutical aims to launch Nabota in over 100 countries by 2020," Park Seong-soo, a company official, said, adding that the company aims to target new and emerging beauty markets.
Nabota -- which is administered via injections -- improves frown lines and arm paralysis by weakening or paralyzing certain muscles or by blocking certain nerves. (Yonhap)
